Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

By: via Benzinga
Press Release Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.